Adjunct Professor, Department of Human Genetics
Director of Research, INSERM, Paris, France
Dominique Gauguier is Adjunct Professor at the Department of Human Genetics and based at the McGill Genome Centre. He was trained at the University Pierre & Marie Curie and the University Denis Diderot in Paris, France, where I received a PhD in human nutrition in 1991. He did his postdoctoral research with Prof Mark Lathrop initially at the INSERM in Paris, France, and, from 1994, at the Wellcome Trust Centre for Human Genetics at the University of Oxford, UK. He was appointed as Oxford University Lecturer (2001), Reader in Mammalian Genetics (2004) and Professor of mammalian genetics (2006). His research at the University of Oxford was supported by two successive highly competitive Wellcome Trust Senior Fellowships between 1999 and 2010. He remains Honorary Research Fellow in Mammalian Genetics at The Wellcome Trust Centre for Human Genetics in Oxford. He is visiting Professor at Imperial College London (UK) and at the Center for Genomic Medicine, at the University of Kyoto (Japan). He currently holds a tenured position of Director of Research at the INSERM in Paris, France, where he leads the research team entitled “Genetic Epidemiology and Functional Genomics of Multifactorial Diseases” at the INSERM UMR 1124 (Environmental Toxicity, Therapeutic Targets, Cellular Signaling and Biomarkers; Prof Robert Barouki, Director)
Gauguier’s research deals with etiological aspects of multifactorial diseases, with a specific focus on risk factors in cardiometabolic diseases. His projects apply in vivo physiology and integrated genomic strategies in model systems to understand the impact of genetic and epigenetic regulations, as well as that of architectural and functional changes in the gut microbiota, on endophenotypes relevant to type 2 diabetes and obesity and recovery from these disease following bariatric surgery. High density data generation metabolomic technologies based on Nuclear Magnetic Resonance (NMR) spectroscopy and mass spectrometry are used as molecular phenotyping tools in rodent genetic models and in human genome wide association studies to identify biomarkers underlying susceptibility and resistance to multifactorial diseases, including metabolites processed by the gut microbiota.
- Venkatachalam, T, O'Sullivan, S, Platt, DE, Ammar, W, Hamadeh, R, Riachi, N et al.. The impact of forced displacement: trauma, increased levels of inflammation and early presentation of diabetes in women Syrian refugees. J Public Health (Oxf). 2023; :. doi: 10.1093/pubmed/fdad037. PubMed PMID:37022674 .
- Al Hageh, C, Chacar, S, Venkatachalam, T, Gauguier, D, Abchee, A, Chammas, E et al.. Genetic Variants in PHACTR1 & LPL Mediate Restenosis Risk in Coronary Artery Patients. Vasc Health Risk Manag. 2023;19 :83-92. doi: 10.2147/VHRM.S394695. PubMed PMID:36814994 PubMed Central PMC9940491.
- Al Hageh, C, Chacar, S, Ghassibe-Sabbagh, M, Platt, DE, Henschel, A, Hamdan, H et al.. Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions. Vasc Health Risk Manag. 2023;19 :31-41. doi: 10.2147/VHRM.S394134. PubMed PMID:36703868 PubMed Central PMC9871050.
- Brial, F, Hedjazi, L, Sonomura, K, Al Hageh, C, Zalloua, P, Matsuda, F et al.. Genetic Architecture of Untargeted Lipidomics in Cardiometabolic-Disease Patients Combines Strong Polygenic Control and Pleiotropy. Metabolites. 2022;12 (7):. doi: 10.3390/metabo12070596. PubMed PMID:35888720 PubMed Central PMC9322850.
- Fromentin, S, Forslund, SK, Chechi, K, Aron-Wisnewsky, J, Chakaroun, R, Nielsen, T et al.. Microbiome and metabolome features of the cardiometabolic disease spectrum. Nat Med. 2022;28 (2):303-314. doi: 10.1038/s41591-022-01688-4. PubMed PMID:35177860 PubMed Central PMC8863577.
- Brial, F, Matsuda, F, Gauguier, D. Diet dependent impact of benzoate on diabetes and obesity in mice. Biochimie. 2022;194 :35-42. doi: 10.1016/j.biochi.2021.12.010. PubMed PMID:34965461 .
- Forslund, SK, Chakaroun, R, Zimmermann-Kogadeeva, M, Markó, L, Aron-Wisnewsky, J, Nielsen, T et al.. Combinatorial, additive and dose-dependent drug-microbiome associations. Nature. 2021;600 (7889):500-505. doi: 10.1038/s41586-021-04177-9. PubMed PMID:34880489 .
- Nuzzo, A, Guedj, K, Curac, S, Hercend, C, Bendavid, C, Gault, N et al.. Accuracy of citrulline, I-FABP and D-lactate in the diagnosis of acute mesenteric ischemia. Sci Rep. 2021;11 (1):18929. doi: 10.1038/s41598-021-98012-w. PubMed PMID:34556697 PubMed Central PMC8460675.
- Brial, F, Chilloux, J, Nielsen, T, Vieira-Silva, S, Falony, G, Andrikopoulos, P et al.. Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health. Gut. 2021;70 (11):2105-2114. doi: 10.1136/gutjnl-2020-323314. PubMed PMID:33975870 PubMed Central PMC8515120.
- Al Hageh, C, Rahy, R, Khazen, G, Brial, F, Khnayzer, RS, Gauguier, D et al.. Plasma and urine metabolomic analyses in aortic valve stenosis reveal shared and biofluid-specific changes in metabolite levels. PLoS One. 2020;15 (11):e0242019. doi: 10.1371/journal.pone.0242019. PubMed PMID:33237940 PubMed Central PMC7688110.